NIKKEI 225
38,747.69 -175.34 (-0.45%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.03 -0.19 (-0.26%) GOLD FUTURES
2,371.90 +2.60 (+0.11%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,826.27 +1,088.69 (+2.06%)
AZN Oct 2024 70.000 put
| Previous close | 1.2800 |
| Open | 0.9200 |
| Bid | 0.8400 |
| Ask | 0.9900 |
| Strike | 70.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.9200 - 0.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 408 |
ZacksAstrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del., June 02, 2024--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
Business WireIMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
WILMINGTON, Del., June 02, 2024--Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT).
